Clinical Trial Update: MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of MGCD0103 (mocetinostat) in elderly patients with previously untreated acute myeloid leukemia/high-risk myelodysplastic syndromes or adults with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• MGCD0103 (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Myelogenous Leukemia, Acute, Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED